SC
SCL Science Inc.
246960 | KO
Overview
Corporate Details
- ISIN(s):
- KR7246960009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 영등포구 선유로13길 25 에이스하이테크시티 2차 1209호, 서울특별시
- Website:
- https://sclscience.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-11 00:00 |
M&A Activity
타법인주식및출자증권취득결정(자율공시)
|
Korean | 16.2 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-14 00:00 |
Regulatory Filings
단일판매ㆍ공급계약체결
|
Korean | 10.4 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.7 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 114.2 KB | ||
| 2025-07-28 00:00 |
Delisting Announcement
주권매매거래정지 (영업양수도)
|
Korean | 4.8 KB | ||
| 2025-07-28 00:00 |
M&A Activity
주요사항보고서(영업양수결정)
|
Korean | 18.8 KB | ||
| 2025-07-21 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(무상증자결정)
|
Korean | 15.0 KB |
Automate Your Workflow. Get a real-time feed of all SCL Science Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SCL Science Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SCL Science Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.
United States of America
IMUX
United States of America
IMUX
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
United States of America
IMVT
Develops novel peptide therapeutics for autoimmune diseases like Lupus (SLE) and CIDP.
United Kingdom
IMM
United Kingdom
IMM
Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.
United States of America
IMMP
United States of America
IMMP
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO
United States of America
IBO
Data mining, bioinformatics, and virtual assistance for the life sciences industry.
South Korea
101140
South Korea
101140
Develops oral cannabinoid/psychedelic therapies for sleep apnea, arthritis & anxiety.
United States of America
IXHL
United States of America
IXHL
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
United States of America
INDP
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
United States of America
IFRX
Inhalation research instruments and CRO services for preclinical pharma/biotech development.
Sweden
ISAB
Sweden
ISAB